APA (7th ed.) Citation

E, D., G, F., A, B., R, G., D, C., S, M., . . . MT, L. (2024). Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: A real-world, single-center experience. Frontiers in oncology, 14, 1391743. https://doi.org/10.3389/fonc.2024.1391743

Chicago Style (17th ed.) Citation

E, Diral, et al. "Sorafenib Maintenance in FLT3-ITD Mutated AML After Allogeneic HCT: A Real-world, Single-center Experience." Frontiers in Oncology 14 (2024): 1391743. https://doi.org/10.3389/fonc.2024.1391743.

MLA (9th ed.) Citation

E, Diral, et al. "Sorafenib Maintenance in FLT3-ITD Mutated AML After Allogeneic HCT: A Real-world, Single-center Experience." Frontiers in Oncology, vol. 14, 2024, p. 1391743, https://doi.org/10.3389/fonc.2024.1391743.